New hope for dravet syndrome: expanded access to seizure drug stiripentol
NCT ID NCT01983722
First seen Jan 23, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This program provides expanded access to the drug stiripentol for people with Dravet syndrome, a severe form of epilepsy that causes frequent, hard-to-control seizures. It is open to patients aged 6 months and older who have not responded to other treatments. The goal is to help reduce seizure frequency and improve quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
Conditions
Explore the condition pages connected to this study.